CRIS

Insider Trades

Name	Value	Action	Price	Current Price
Kaitin Kenneth IDirector $5.5k10k shares BuyMar 31, 2026 $0.5487 --

News

seekingalpha.comCuris, Inc. (CRIS) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 13

prnewswire.comCuris Provides First Quarter 2026 Business Updateprnewswire.comMay 12

prnewswire.comCuris to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026prnewswire.comMay 5

zacks.comKiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimateszacks.comApr 28

zacks.comCuris (CRIS) Upgraded to Buy: What Does It Mean for the Stock?zacks.comApr 15

Trade CRIS

About Curis, Inc.

Curis, Inc. is a biotechnology firm dedicated to identifying and advancing therapeutic compounds for various human cancers across the United States. Its current clinical-stage pipeline features Emavusertib, an oral small molecule presently in Phase 1/2 trials for treating non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Another significant candidate is CI-8993, a monoclonal antibody designed to counteract the V-domain Ig suppressor of T cell activation. The company's broader development initiatives also encompass Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes, being developed for patients with MYC-altered diffuse large B-cell lymphoma. Additional candidates include CA-170, an oral small molecule aimed at advanced solid tumors and lymphomas, and CA-327, an oncology drug in its pre-investigational new drug phase. Curis has established key collaborative agreements, notably with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the co-development and marketing of Erivedge, an orally administered small molecule that inhibits the hedgehog signaling pathway for advanced basal cell carcinoma. Furthermore, it partners with Aurigene Discovery Technologies Limited on the research, development, and commercialization of small molecule compounds within the immuno-oncology and precision oncology sectors. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

CEO: James E. Dentzer
IPO Date: Aug 1, 2000

Market Data

Open: $0.4079
High: $0.4459
Low: $0.38
Volume: 709.6K
Avg Volume: 517.9K
52W High: $2.48
52W Low: $0.38

Valuation

Market Cap: $5.5M
Enterprise Value: $-8.1M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-27M
Revenue: $9.4M
Net Income: $-7.6M
Cash: $5.1M
Debt: $1.6M

Events

EarningsAug 4

EPS est. -0.34667